A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly  by Maruyama, T. et al.
Respiratory Medicine (2008) 102, 1287e1295ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedA prospective comparison of nursing home-acquired
pneumonia with hospital-acquired pneumonia in
non-intubated elderlyT. Maruyama a, M.S. Niederman f, T. Kobayashi a, H. Kobayashi a,
T. Takagi a, C.N. D’Alessandro-Gabazza a, H. Fujimoto a, P. Gil Bernabe b,
S. Hirohata d, S. Nakayama d, K. Nishikubo d, H. Yuda e, A. Yamaguchi a,
E.C. Gabazza c,*, T. Noguchi d, Y. Takei b, O. Taguchi aa Department of Pulmonary and Critical Care Medicine, Mie University Graduate School of Medicine,
Edobashi 2-174, Tsu City, Mie Prefecture, Japan
b Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine,
Edobashi 2-174, Tsu City, Mie Prefecture, Japan
c Department of Immunology, Mie University Graduate School of Medicine, Edobashi 2-174,
Tsu City, Mie Prefecture, Japan
d Kinan General Hospital, 4750 Atawa, Mihama-chou, Minamimuro, Mie, 519-5293, Japan
e Mie Prefecture General Hospital, 5450-132 Hinaga, Yokkaichi, Mie, 510-0885, Japan
f Department of Medicine, Winthrop University Hospital, 222 Station Plaza N., Suite 5091, Mineola, NY 11501, USA
Received 5 January 2008; accepted 28 March 2008
Available online 7 July 2008KEYWORDS
Pneumonia;
Non-intubated
patients;
Prognosis;
Elderly* Corresponding author. Department
Tel.: þ81 59 231 5017; fax: þ81 59 23
E-mail address: gabazza@clin.med
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2008.03.027Summary
There are no prospective comparison of the etiology and clinical outcome between hospital-
acquired pneumonia (HAP) and nursing home-acquired pneumonia (NHAP) in non-intubated el-
derly. This study prospectively evaluated the etiology of HAP and NHAP in non-intubated
elderly. A prospective cohort study was carried out in a rural region of Japan where the popu-
lation over 65 years of age represents 30% of the population. A total of 108 patients were en-
rolled. There were 33 patients with HAP and 75 with NHAP. Etiologic diagnosis was established
in 78.8% of HAP and in 72% of NHAP patients. The most frequent pathogens were Chlamydophi-
la pneumoniae followed by Streptococcus pneumoniae, Staphylococcus aureus and Influenza
virus. The frequency of Streptococcus pneumoniae and Influenza virus was significantly higher,
whereas the frequency of Staphylococcus aureus and Enterobacteriaceae was significantly
lower in NHAP compared to HAP. Performance and nutritional status were significantly worse
in patients with HAP than in those with NHAP. Hospital mortality was significantly lower inof Immunology, Mie University School of Medicine, Edobashi 2-174, Tsu city, Mie 514-8507, Japan.
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ic.mie-u.ac.jp (E.C. Gabazza).
8 Elsevier Ltd. All rights reserved.
1288 T. Maruyama et al.patients with NHAP compared to those with HAP. This study demonstrated that C. pneumoniae,
Streptococcus pneumoniae, Staphylococcus aureus and Influenza virus are frequent causative
agents of pneumonia in non-intubated elderly and that the responsible pathogens and clinical
outcome differ between NHAP and HAP.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
The population over 65 years of age will increase rapidly in
the next half century in developed countries. The increase in
the elderly population is going to be particularly conspicuous
in Japan where people over age 65 will exceed 30% of the
population in the year 2040. One consequence of this trend
would be crowding of nursing homes and general hospitals
and frequent outbreaks of infectious diseases such as pneu-
monia due to impaired host defense mechanisms in the
elderly. Aging and environmental factors affect themorbidity
and mortality rates of infectious diseases including pneumo-
nia. For example, nursing home-acquired pneumonia (NHAP)
has an incidence of 33e114 per 1000 and a mortality rate of
13e57%,while hospital-acquired pneumonia (HAP) has amor-
bidity of 5e10 per 1000 and a mortality rate of 30e70%.1,2
The reported microbial etiology of HAP and NHAP is based
on data obtained in samples taken by bronchoscopic exam-
ination in patients with ventilator-associated pneumonia
(VAP).1,3,4,5,6 Patientswith NHAPare one formof healthcare-
associated pneumonia (HCAP), and the ATS/IDSA guidelines
for nosocomial pneumonia suggest that HCAP be treated as
a form of HAP, using antimicrobial regimens similar to those
used for patients with late-onset HAP.1 Previous studies
have documented that HCAP is not similar bacteriologically
to CAP, but HCAP patients have had a variably reported
frequency of drug-resistant gram-negatives and Staphylo-
coccus aureus, and it remains uncertain if these patients
really have the same bacteriology as late-onset HAP
patients.7,8 While previous studies have established the
differences between community-acquired pneumonia
(CAP) and HCAP, there is no direct prospective evaluation
to determine if the bacteriology of NHAP is really similar to
the bacteriology of late-onset HAP in non-intubated
patients.9 In the present study, we hypothesized that the
causative pathogens of HAP are different from those of
NHAP in non-intubated elderly patients. The rationale for
this hypothesis is that hospitalized patients are generally
admitted because of acute disease and undergo frequent
invasive procedures whereas residents of nursing homes gen-
erally have physical disability due to chronic disorders or
aging, but may not routinely have the same degree of host
impairment as hospitalized patients. To evaluate our hypoth-
esis, we carried out a prospective and comparative study of
NHAP and HAP in non-intubated patients in a community
where 30% of the population is 65 years of age.
Methods
Patients
The present study was conducted between June 2004 and
May 2005 at the KinanGeneral Hospital, an affiliated hospitalof Mie University. Kinan is located in a rural region of Japan
where the population over 65 years of age is about 30%.
Informed consent was obtained from all patients and the
study was approved by the Committee for Ethics and Clinical
Investigation of Kinan Hospital. All procedures used were in
accordance with the recommendations of the Helsinki
Declaration.
A total of 268 patients with a suspected diagnosis of
pneumonia were enrolled, including 33 patients with HAP
and 75 with NHAP. One hundred sixty patients were
excluded because they were diagnosed as having CAP
(nZ 151), organizing pneumonia (nZ 5), interstitial pneu-
monia (nZ 1), bronchiolitis obliterans with organizing
pneumonia (nZ 1), terminal renal cancer (nZ 1); four
cases under hemodialysis were also excluded.
The diagnosis of pneumonia was based on the following
criteria: (1) the presence of symptoms of lower respiratory
tract infection, (2) a radiographic infiltrate compatible with
pneumonia, (3) the presence of fever (>38 C), leukocyto-
sis (>11.0 109/L), leucopenia (<3.5 109/L), purulent
sputum, change in character of respiratory secretions or
increased arterial-alveolar gradient.10 All patients
(nZ 268) were required to have radiographic pneumonia.
Among HAP patients, four were in the intensive care unit
(ICU) and 29 in general ward, and among NHAP patients,
six were in ICU and 69 in general ward. Antibiotics used
prior to hospitalization are described in Supplementary
Table 1.
Late-onset hospital-acquired pneumonia (HAP) was
defined as pneumonia that occurred 5 days or more after
admission to hospital. Late-onset nursing home-acquired
pneumonia (NHAP) was defined as pneumonia that occurred
5 days or more after admission to the nursing home.
Excluded from the study were patients with a history of
pneumonia that occurred within the 2 months prior to
admission; patients with early-onset HAP or NHAP, VAP or
CAP; and those with malignant disease, acute congestive
heart failure, pulmonary infarction, interstitial pneumonia,
aspiration pneumonia or lung cancer-associated obstructive
pneumonia. Patients with severe immunosuppression (neu-
trophils <1.0 109/L), human immunodeficiency (HIV)
infection, solid-organ or bone-marrow transplantation or
those under dialysis or steroid therapy (dose >10 mg pred-
nisone-equivalent per day for 2 or more weeks) were also
excluded from the study.Collection of data
Clinical, radiological and laboratory data including age, sex,
performance status (European Cooperative Oncology Group
(ECOG)), underlying disease, antimicrobial treatment prior
to hospital admission, duration of symptoms before the
diagnosis of pneumonia, clinical symptoms, physical
Pneumonia in non-intubated elderly 1289findings, blood gas analysis, chest X-ray and computed
tomography findings were recorded in computer software
for subsequent analysis. Criteria of the ECOG: Grade 0: fully
active, able to carry on all pre-disease performance without
restriction; Grade 1: restricted in physically strenuous
activity but ambulatory and able to carry out work of a light
or sedentary nature (e.g., light house work, office work);
Grade 2: ambulatory and capable of all selfcare but unable to
carry out any work activity up and about more than 50% of
waking hours; Grade 3: capable of only limited selfcare,
confined to bed or chair more than 50% of waking hours;
Grade 4: completely disabled, unable to carry on any
selfcare, totally confined to bed or chair; Grade 5: dead.11
Microbiologic evaluation
Sputum, urine and two samples of blood were drawn for
microbiologic examination after admission. Sputum
samples were taken into consideration when Gram staining
showed numerous leukocytes (>25 in high power micro-
scopic field) and few epithelial cells (<10 in high power
microscopic field).
Diagnostic criteria
The results of both culture and Gram staining were taken
into consideration for microbial diagnosis; heavy growth
(107 cfu/ml) in culture of a predominant bacterium from
sputum having a Gram staining was considered as consis-
tent with a presumptive pathogen. The etiological diagno-
sis was considered as definitive when the following criteria
were fulfilled: (1) blood culture positive for bacteria or
fungi (in the absence of an apparent extrapulmonary
focus); (2) positive culture for bacteria in samples of pleu-
ral fluid or transthoracic needle aspiration; (3) positive
culture of tuberculosis in respiratory samples; (4) sero-
conversion (four-fold increase in the serum level of IgG)
against Chlamydophila pneumoniae, Chlamydophila psit-
taci, Mycoplasma pneumoniae, Cytomegalovirus, Influenza
virus A (H1N1, H3N2) and B (B-1), Parainfluenza virus 3,
Respiratory syncitial-virus, Adenovirus; (five-fold increase
in the serum level of IgM) against C. pneumoniae (1:64),
M. pneumoniae (any positive titer) by enzyme-linked
immunosorbent assay; (5) positive urinary antigen for
Streptococcus pneumoniae and Legionella pneumophila;
and (6) bacterial growth in culture of protected
specimen brush (103 cfu/ml) or bronchoalveolar lavage
fluid (105 cfu/ml).
Statistical analysis
Data were expressed as the mean  standard deviation of
the mean and analyzed using the StatView package
software. Univariate analysis was carried out using the
chi-square test or Fishers exact test for categorical data
and the ManneWhitney U-test for continuous variables.
Multivariate analysis for age and sex adjustment was
performed by logistic regression analysis. Prognostic factors
were analyzed by logistic regression. All reported p values
are two-tailed. A p value of <0.05 was considered as statis-
tically significant.Results
Patient characteristics
A total of 268 patients with a suspected diagnosis of
pneumonia were enrolled, including 33 patients with HAP
and 75 with NHAP. The age of the patients with NHAP
(87.3 8.9 years old) was significantly different from that
of patients with HAP (79.0 7.2 years old). Performance
status (European Cooperative Oncology Group (ECOG))
was significantly worse in HAP than in NHAP group (Table
1).11 Underlying cerebrovascular diseases were significantly
more frequent in NHAP than in the HAP group (Table 1). The
site of care of patients did not affect clinical outcome in
HAP or NHAP patients (data not shown). Antibiotic therapy
prior to admission had been given to 26 patients with NHAP
(meanZ 4.3 1.6 days) and to 14 patients with HAP
(meanZ 5.5 1.8 days) (Supplementary Table 1); how-
ever, mortality was not affected by previous administration
of antibiotics (Supplementary Table 2).
Clinical and laboratory findings at presentation
Fever, alteration ofmental status, dyspnea, cough and sputum
were themost common symptoms in all patients. Alteration of
mental status was more commonly present in HAP than in
NHAP. The systolic blood pressure, mean blood pressure, the
red blood cell count, lymphocyte count, and the blood
concentration of hemoglobin, albumin, cholinesterase were
significantly lower in HAP than in the NHAP group (Table 2).
Etiology of pneumonia
A microbiologic diagnosis was established in 78.8% (26/33)
of patients with HAP and in 72% (54/75) of patients with
NHAP. The diagnosis was definitive in 69.7% (23/33) and
presumptive in 12.1% (4/33) of patients with HAP, and
69.3% (52/75) and 2.7% (2/75) of patients with NHAP,
respectively. Mixed population of pathogens was detected
in 39.4% (13/33) of patients with HAP and 38.7% (29/75) of
patients with NHAP. There was a trend (pZ 0.0577) for
more bacterial pathogens in HAP (63.6%) than in the NHAP
(37.3%) group. Among all patients, the most frequent path-
ogens were C. pneumoniae (32.4%) followed by Streptococ-
cus pneumoniae (26.9%), Staphylococcus aureus (11.1%)
and Influenza virus (11.1%) (Table 3). The frequency of
Streptococcus pneumoniae (33.3 vs. 12.1%) and Influenza
virus (14.7 vs. 3%) was significantly high, whereas the
frequency of Staphylococcus aureus (4.0 vs. 27.2%) and
Enterobacteriaceae (4.0 vs. 21.2%) was significantly low in
NHAP compared to HAP after adjusting for age and sex.
C. pneumoniae was almost equally frequent in both NHAP
(34.7%) and HAP (27.3%) (Table 3). Performance and nutri-
tional status were significantly worse in patients with HAP
than in those with NHAP.
Prognosis
The age and sex were significantly different between HAP
and NHAP, thus we compared mortality between both
groups after correcting for age and sex using logistic
Table 1 Patient characteristics
All patients
nZ 108 (%)
HAP
nZ 33 (%)
NHAP
nZ 75 (%)
p Valuea p Valueb
Age years 85.0 9.2 79.0 7.2 87.3 8.9 <0.0001 e
Range years 62e102 64e94 62e102 e e
Sex M 51 (47.2) 24 (72.7) 24 (36.0) 0.0004 e
ECOG (1e4) 3.1 0.6 (1e4) 3.4 0.5 (3e4) 3.0 0.5 (1e4) <0.0001 0.0002
Grade 1 1 (0.9) 0 1 (1.3)
Grade 2 9 (8.3) 0 9 (10.7)
Grade 3 72 (66.7) 16 (48.5) 56 (74.7)
Grade 4 26 (24.1) 17 (51.5) 9 (12.0)
Prior antibiotics 40 (37.0) 14 (42.4) 26 (34.7) 0.4419 0.4256
Influenza vaccination in last 1 year 88 (81.5) 23 (69.7) 65 (86.7) 0.0365 0.2816
Pneumococcal vaccination in last 10 years 0 0 0 e e
Comorbid illnesses
Cerebrovascular disease 39 (36.1) 7 (21.2) 32 (42.7) 0.0325 0.040
Chronic pulmonary disease 14 (13.0) 5 (15.1) 9 (11.3) 0.6533 0.6686
Malignancy 5 (4.6) 5 (15.1) 0 0.0021 0.9962
Psychological disorder 6 (5.6) 5 (15.1) 1 (1.3) 0.0099 0.0701
Diabetes melitus 11 (10.2) 4 (12.1) 7 (9.3) 0.7332 0.7461
Congestive heart failure 14 (13.0) 2 (6.0) 12 (16.0) 0.2190 0.9966
Chronic liver disease 2 (0.5) 2 (6.0) 0 0.0914 0.9965
Chronic renal disease 3 (2.8) 0 3 (4.0) 0.5514 0.9958
Gastrostomy 5 (4.6) 2 (6.0) 3 (4.0) >0.9999 0.7351
No. of comorbid illness
None 11 (10.2) 0 11 (14.7) 0.0172 0.4354
1 44 (40.7) 17 (51.5) 27 (36.0)
2 38 (35.2) 12 (36.4) 26 (34.7)
3 15 (13.9) 4 (12.1) 11 (14.7)
All data are presented as n (%)and mean  SD unless otherwise stated.
HAP: Hospital-acquired pneumonia; NHAP: Nursing home-acquired pneumonia; M: Male.
a Not age and sex adjusted.
b Age and sex adjusted.
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significantly higher (pZ 0.0213) in HAP (51.5%) than in
NHAP after adjusting for age and sex (37.3%) (Table 4).
However, when the ECOG (odd ratioZ 0.67, pZ 0.5) or
CURB-65 [(C: confusion, U: uremia, R: respiratory rate, B:
low blood pressure, 65: 65 years or more); odd ratioZ 0.43,
pZ 0.13] or both factors (odd ratioZ 0.90, pZ 0.90) were
included in the logistic equation, no significant difference
in-hospital mortality was observed between both groups.
This loss of mortality differences after controlling for
ECOG and CURB-65 is a way of demonstrating that these
factors, which are associated with HCAP, account for the
main differences in the populations. Multivariate analysis
was performed taking into consideration the following vari-
ables: age, sex, establishment (hospital or nursing home),
performance status (ECOG score), body temperature,
systolic blood pressure, oxygenation index, nutritional
status (albumin), immune status (lymphocyte), dehydration
(blood urea nitrogen). ECOG, albumin, oxygenation index
and blood urea nitrogen were independent and significant
predictors of prognosis in all patients (Table 5). ECOG
score, dehydration and albumin were also independent
prognostic factors when the logistic regression analysis
was performed in the NHAP group alone (Table 6).The severity of pneumonia was also evaluated in the
NHAP group using the pneumonia severity index.12 This
evaluation showed that the in-hospital mortality was sig-
nificantly higher in NHAP patients in risk class V compared
to patients in risk class IV (Supplementary Table 3). CURB-
65 score was also used to assess the severity of pneumo-
nia; this score was found to be significantly higher in
HAP than in NHAP (Table 7). The therapy used in the
HAP and NHAP groups is described in Supplementary Table
4. Patterns of antibiotic use were similar in both groups,
although those with NHAP tended to get more dual therapy
than those with HAP, while those with HAP tended to re-
ceive more carbapenems and less cephalosporin than those
with NHAP. Therapy with macrolides and minocycline were
given to more than half of both the HAP and NHAP pa-
tients. Response to the initial empiric antimicrobial ther-
apy was evaluated after 3 days based on changes of
body temperature, symptoms and white blood cell count.
No substantial difference was observed in response rates
to therapy between the two groups of patients. HAP
(44.4%) and NHAP (53.8%) patients with C. pneumoniae
were initially treated with macrolide/minocycline, the re-
sponse rate being 25% in HAP and 71.4% in NHAP; however,
the mortality rate was not affected by this initial
Table 2 Clinical findings on presentation
All patients
nZ 108 (%)
HAP
nZ 33 (%)
NHAP
nZ 75 (%)
p Valuea p Valueb
Symptoms on presentation
Fever 79 (73.1) 25 (75.7) 54 (72) 0.6848 0.4354
Sputum production 75 (69.4) 24 (72.7) 51 (68.0) 0.6232 0.5123
Cough 48 (44.4) 19 (57.6) 29 (38.7) 0.0685 0.1370
Dyspnea 46 (42.6) 12 (36.3) 34 (45.3) 0.3852 0.4354
Altered mental status 29 (26.9) 15 (45.5) 14 (18.7) 0.0038 0.0023
Temperature C 37.9 0.8 38.0 0.8 37.9 0.8 0.4415 0.8831
Heart rate/min 94.2 18.9 99.4 25.4 91.9 15.0 0.1953 0.1019
SBP mmHg 121.5 28.7 104.0 24.0 128.9 27.6 <0.0001 0.0004
DBP mmHg 68.1 15.8 63.1 10.9 69.9 17.1 0.1181 0.1556
MBD mmHg 95.7 19.6 84.1 16.4 100.0 19.1 0.0004 0.0045
RR/min 26.0 8.0 26.0 7.0 26.0 8.0 0.6365 0.6287
PaO2/FiO2 259.4 98.4 250.6 118.9 263.2 89.6 0.8012 0.9329
Red blood cell104/ml 348 62.9 317 62.3 360 59.3 0.0016 0.0004
Hemoglobin g/dl 10.9 2.0 10.1 2.7 11.2 1.6 0.0001 0.0088
Hematocrit % 32.3 5.5 29.2 5.7 33.74.9 0.0001 0.0002
White blood cell/ml 10,479.6 5108.8 11,457 5696.4 10,049 4482.0 0.2844 0.07
Neutrophil/ml 8593.5 5065.2 9549 6019.4 8163.3 4590.4 0.4050 0.055
Lymphocyte/ml 1043.3 640.4 795.5 481.5 1148.0.0 677.0 0.0103 0.0080
Total protein g/dl 6.18 0.70 6.06 0.67 6.22 0.70 0.3291 0.1947
Albumin g/dl 2.97 0.45 2.82 0.43 3.04 0.44 0.0136 0.0248
Total cholesterol mg/dl 143 39.1 127 31.2 147 40.5 0.0183 0.0831
Cholinesterase IU/l 159 82.3 127 81.0 169 81.3 0.003 0.0184
Creatine phosphokinase IU/l 254 507 250.7 502.6 254.8 515.2 0.1444 0.3387
Blood urea nitrogen mg/dl 23.7 15.5 23.3 12.9 23.9 16.7 0.5776 0.8642
Creatinine mg/dl 0.90 0.56 0.82 0.31 0.93 0.64 0.8589 0.3708
Sodium mEq/l 138 7.6 135 9.5 139 6.3 0.0288 0.0591
Potassium mEq/l 3.87 0.7 3.92 0.72 3.85 0.69 0.3619 0.5727
Chloride mEq/l 99 11.3 94.6 18.3 101 5.6 0.0252 0.0687
Glucose mg/dl 142.6 66.7 156.8 56.6 139.7 68.9 0.1293 0.3290
C-reactive protein mg/dl 13.1 7.7 13.9 8.2 12.8 7.5 0.5155 0.9808
All data are presented as n (%) and mean  SD.
HAP: hospital-acquired pneumonia; NHAP: nursing home-acquired pneumonia; SBP: systolic blood Pressure; DBP: diastolic blood
pressure; MBP: mean blood pressure; RR: respiratory rate.
a Not age and sex adjusted.
b Age and sex adjusted.
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mentary Table 5). The prevalence of multi-drug resistance
(MDR) was compared between HAP and NHAP patients; c2
analysis showed significantly more MDRþ in HAP (24.2%;
nZ 8) than in NHAP (9.3%; nZ 7). To identify risk factors
for MDR pathogens, NHAP patients were categorized into
MDRþ (nZ 7) and MDR (nZ 68) groups; no specific risk
factors for MDR were identified in these patients; however,
the number of NHAP is too low to allow risk factor
identification.Discussion
We have reported the natural history, bacteriology and
therapy of a population of non-intubated patients with both
NHAP and HAP hospitalized in a single hospital in a region of
Japan with a high frequency of elderly individuals. We
observed that patients with NHAP had a significantly lowermortality rate than patients with HAP, and that functional
status, nutritional status, oxygenation and hydration were
important mortality predictors for the entire group of
patients. We also saw differences in bacteriology between
the groups, with an etiologic diagnosis having been estab-
lished in over 70% of all patients. Those with NHAP tended
to have more Streptococccus pneumoniae, and less Staphy-
lococcus aureus and enteric gram-negatives than those with
HAP. Interestingly, both groups had a high frequency of
infection with C. pneumoniae. In general, the early
response to therapy was similar in both groups, but those
with HAP tended to receive more carbapenems, and less
cephalosporin than those with NHAP, although over half of
both groups received therapy with a macrolide or minocy-
cline. Although the ATS/IDSA nosocomial pneumonia guide-
lines suggest that NHAP be considered an illness that should
be treated similar to late-onset HAP, our findings do not
support this. We found a lower frequency of Staphylococcus
aureus and enteric gram-negatives in NHAP, compared to
Table 3 Causative microorganisms
All patients
nZ 108 (%)
HAP
nZ 33 (%)
NHAP
nZ 75 (%)
p Valuea p Valueb
Bacterial pathogens 49 (45.4) 21 (63.6) 28 (37.3) 0.0114 0.0577
Streptococcus pneumonia 29 (26.9) 4 (12.1) 25 (33.3) 0.0332 0.031
Staphylococcus aureus 12 (11.1) 9 (27.2) 3 (4.0) 0.001 0.0064
Enterobacteriaceae 10 (9.3) 7 (21.2) 3 (4.0) 0.0085 0.0252
Pseudomonas aeruginosa 5 (4.6) 4 (12.1) 1 (1.3) 0.0297 0.0754
Acinetobacter sp 2 (1.9) 2 (6.0) 0 0.0914 0.9952
Haemophilus influenzae 1 (0.9) 1 (3.0) 0 0.3056 e
Moraxella catarrhalis 2 (1.9) 0 2 (2.7) >0.9999 0.9966
Anaerobes 0 0 0 e e
Others 6 (5.6) 3 (9.0) 3 (4.0) e e
Atypical pathogens 38 (35.2) 10 (30.3) 28 (37.3) 0.4810 0.7301
Chlamydophila pneumoniae 35 (32.4) 9 (27.3) 26 (34.7) 0.495 0.7299
Chlamydophila psittaci 0 0 0 e e
Mycoplasma pneumoniae 10 (9.3) 3 (9.0) 7 (9.3) >0.9999 0.8114
Legionella pneumophila 0 0 0 e e
Viral pathogens 28 (25.9) 7 (21.2) 21 (28.0) 0.4584 0.3748
Cytomegalovirus 9 (8.3) 3 (9.0) 6 (8.0) >0.9999 0.8618
Influenza virus 12 (11.1) 1 (3.0) 11 (14.7) 0.1009 0.0477
Respiratory syncytial virus 5 (4.6) 2 (6.0) 3 (4.0) 0.6402 0.2044
Parainfluenza virus 3 4 (3.7) 1 (3.0) 3 (4.0) >0.9999 0.4615
Adeno virus 0 0 0 e e
Tuberculosis 0 0 0 e e
Fungal pathogens 3 (2.8) 1 (3.0) 2 (2.7) >0.9999 0.7854
All data are presented as n (%) unless otherwise stated.
HAP: hospital-acquired pneumonia; NHAP: nursing home-acquired pneumonia.
Numbers include mixed population of pathogens: 13 in HAP and 29 in NHAP. Staphylococcus aureus included methicillin-sensitive 3 and
methicillin-resistant 6 in HAP, and methicillin-sensitive 2 and methicillin-resistant 1 in NHAP. Enterobacteriaceae included Klebsiella
pneumoniae 4. Serratia marcescens 1, Escherichia coli 1, Proteus mirabilis 1 in HAP, and Klebsiella pneumoniae 3 in NHAP. Other in-
cluded Stenotrophomonas maltophilia 1, Coagulase-negative staphyloccocci 1, Microccus spp. 1, and Streptococcus agalactiae (Group
B) 2, Corynebacterium spp. 1, Influenza virus included Influenza virus A 1 in HAP, and Influenza A 4 and Influenza B 9 in NHAP. Fungal
pathogens included Aspergillus spp. 1 in HAP, and Aspergillus spp. 1 and Candida albicans 1 in NHAP.
a No adjusted for age and sex.
b Adjusted for age and sex.
1292 T. Maruyama et al.HAP, and only seven of 77 NHAP patients harbored MDR
pathogens.
Previous studies have speculated that the microbial
etiology of NHAP is similar to that described in patients
with VAP or late-onset HAP.1,3,6 For example, El-Solh et al.3
carried out a comparative study between patients with
NHAP and CAP requiring mechanical ventilation, and found
that the most frequent causative agents of NHAP areTable 4 Logistic regression analysis to compare prognosis betw
Prognostic
factor
Coefficient Standard
error
Chi-s
Age years 0.123 0.032 15.16
Sex (M) 0.880 0.496 3.14
In-hospital
mortality
1.197 0.520 5.30
HAP: nZ 33 (died 17, survived 16).
NHAP: nZ 75 (died 28, survived 47).Staphylococcus aureus (29%) and Gram-negative enteric ba-
cilli (15%) with a low frequency of Streptococcus pneumo-
niae (9%) and almost no detection of atypical
microorganisms and virus. In addition, Chastre et al.6 per-
formed a meta-analysis of 24 studies and reported Pseudo-
monas aeruginosa (24.4%), Staphylococcus aureus (20.4%),
and Enterobacteriaceae (14.1%) as the most common caus-
ative agents of VAP. Based on these results, statements ofeen patients with HAP and NHAP
quare p Value Odds
ratio
95% CI
1 <0.0001 1.131 1.063e1.204
2 0.0763 0.415 0.157e1.098
3 0.0213 0.302 0.109e0.837
Table 5 Logistic regression analysis to evaluate prognostic factors in all patientsa
Prognostic factor Coefficient Standard
error
Chi-square p Value Odds ratio 95% CI
Age years 0.077 0.042 3.477 0.0622 1.081 0.996e1.172
Sex (M) 0.494 0.613 0.649 0.4205 0.610 0.183e2.030
Environment (HAP) 0.706 0.835 0.715 0.3978 2.026 0.394e10.404
ECOG (1e4) 2.137 0.681 9.836 0.0017 8.477 2.229e32.238
Temperature C 0.016 0.344 0.002 0.9628 1.016 0.518e1.993
SBP mmHg 0.016 0.012 1.350 0.1823 1.016 0.993e1.040
PaO2/FiO2 0.007 0.003 4.555 0.0328 0.993 0.987e0.999
Blood urea nitrogen mg/dl 0.037 0.018 4.513 0.0336 1.038 1.003e1.074
Albumin g/dl 1.353 0.661 4.189 0.0407 0.258 0.071e0.944
Lymphocyte/ml 0.0002369 0.0004648 0.260 0.6102 1.000 0.999e1.001
HAP: Hospital-acquired pneumonia; M: male; ECOG: European Cooperative Oncology Group; SBP: Systolic blood pressure.
a HAP þ NHAP, nZ 108 (died 45, survived 63).
Pneumonia in non-intubated elderly 1293the ATS/IDSA described bacterial pathogens as the most
frequent causes of VAP, HAP and HCAP (NHAP) with a lower
frequency of virus and fungi.1 Recently, Micek et al.7 and
Carratala` et al.8 have compared the bacteriology of HCAP
to CAP, with variable findings with regard to whether MDR
pathogens are common in HCAP patients. However, no
study has prospectively evaluated NHAP and HAP, using
the same methods in non-intubated patients, as we have
done in this study.
Strict evaluation of the causative pathogens of NHAP and
HAP in non-intubated elderly is lacking; probably because
of the difficulty in obtaining appropriate sputum samples
from the elderly. In the present study, appropriate sputum
samples from patients with NHAP were obtained in 26.7%
(20/75) of the NHAP patients, and in 51.5% (17/33) of those
with HAP. In addition, in our present study, we carried out
a complete screening of urinary antigens, serum antibodies
and blood culture for identifying the causative agent; this
screening allowed the identification of the causative
organism in 78.8% of HAP patients and 72.0% of NHAP
patients. Although there is some controversy about the use
of serologic data to define the presence of Chlamydophila
infection, we applied our methodology to both HAP and
NHAP patients, and there are prior reports of this pathogen
in NHAP patients.13,14 To our knowledge, this is the first
study that has prospectively assessed the causativeTable 6 Logistic regression analysis to evaluate prognostic fact
Prognostic factor Coefficient Standard
error
Chi-
Age years 0.006 0.053 0.01
Sex (M) 1.360 0.881 2.38
ECOG (1e4) 3.983 1.366 8.49
Temperature C 0.065 0.533 0.01
SBP mmHg 0.043 0.021 3.98
PaO2/FiO2 0.006 0.005 1.51
Blood urea nitrogen
mg/dl
0.070 0.024 8.38
Albumin g/dl 4.223 1.475 8.19
Lymphocyte/ml 0.001 0.001 0.55
HAP: Hospital-acquired pneumonia; M: male; ECOG: European Coope
a nZ 75 (died 28, survived 47).pathogens including bacteria, atypical microorganism, virus
and fungi in non-intubated and non-immunocompromised
patients with NHAP and HAP in a community where 30% of
the population is 65 years old.
In the present study, unlike previous studies, we found
high frequency of Chlamydophila infection despite using
a criterion stricter than that usually recommended (IgG:
four-fold; IgM:64-fold).15 There may be several explana-
tions for the discrepancy with previous reports. One reason
may be inferred from the fact that most of previous studies
have been focused on intubated patients under mechanical
ventilation since there is no report on the actual frequency
of Chlamydophila pneumoniae in non-intubated patients.
Based on this, it is possible to speculate that non-intubated
patients, as those of the present study,may bemore exposed
to contaminated environments or to person-to-person trans-
mission than intubated patients. An outbreak of Chlamydo-
phila pneumoniae in nursing homes reported in a previous
study supports this assumption.13 Differences with findings
reported by Ishida et al. and Song et al. may be explained
by the fact that in these previous studies the presence of
Chlamydophila was evaluated by ELISA, which is not a sensi-
tive method for the detection of the pathogen.16,17 In addi-
tion, measurement of both IgG and IgM is currently
recommended for the diagnosis of Chlamydophila pneumo-
niae; the absence of cases of Chlamydophila pneumoniaeors in the NHAP groupa
square p Value Odds ratio 95% CI
3 0.9078 1.006 0.908e1.115
3 0.1226 0.257 0.046e1.443
9 0.0036 53.698 3.688e781.851
5 0.9025 0.937 0.330e2.663
7 0.0459 1.044 1.001e1.089
0 0.2191 0.994 0.985e1.003
2 0.0038 1.073 1.023e1.125
5 0.0042 0.015 0.001e0.264
3 0.4573 0.999 0.998e1.001
rative Oncology Group; SBP: Systolic blood pressure.
Table 7 Evaluation of severity of disease by CURB-65
HAP
nZ 33 (%)
In-hospital
mortality (%)
NHAP
nZ 75
In-hospital
mortality (%)
CURB-65 score 2.54 1.37* 17/33 (51.5) 1.95 1.03 28/75 (37.3)
0 1 0/1 (0) 2 0/2 (0)
1 10 4/10 (40) 26 5/26 (19.2)
2 4 2/4 (50) 29 11/29 (37.9)
3 7 3/7 (42.9) 11 8/11 (72.7)
4 10 7/10 (70) 6 3/6 (50.0)
5 1 1/1 (100) 1 1/1 (100)
*pZ 0.0343, compared to NHAP.
Supplementary data
Supplementary data associated with this article can be
found in the online version at 10.1016/
j.rmed.2008.03.027.
1294 T. Maruyama et al.in the report by Martinez-Moragona et al. may be explained
by the fact that they measured IgG but not IgM for making
the diagnosis of the pathogen.18
Delay in the diagnosis and therapy of pneumonia commonly
occurs in theelderlydue tothe frequentabsenceof respiratory
symptoms (e.g., dyspnea, fever, cough).14 Similarly, the ma-
jority of our patients complained of no symptoms and thus di-
agnosis of the infectious disease was only suspected after
completion of the medical examination. Neurological symp-
toms (e.g., delirium) may also hamper the early diagnosis of
thedisease.The significantassociationbetweenhighmortality
rate and ECOG score reported among patientswith pneumonia
illustrates the importanceofperformancestatus in theprogno-
sis of these patients.14,18,19 In fact, in some studies of NHAP,
poor functional status has correlated with the presence of
MDRpathogens.3 The fact that NHAPpatients had a better per-
formance status thanHAPpatientsmaybe related to the lower
frequency of MDR pathogens in the NHAP population than
might have been expected. Malnutrition is another factor
that may affect prognosis apart from being a risk factor for
pneumonia. The incidence of malnutrition is four˜six-fold
higher in patients admitted to hospitals or nursing homes com-
pared to elderly people from the general community.20 Ri-
quelme et al.23 evaluated the nutritional status in 101
individuals 65 years old and found that hypoalbuminemia
wasa risk factor forpneumonia and that itworsens clinical out-
come. Evaluation of clinical outcome disclosed high mortality
rate in HAP compared to NHAP patients; consistent with this
finding, Kobashi et al. also found higher mortality in 125 pa-
tients with HAP (nZ 125) than in those with NHAP (nZ 45).21
El-Solh et al.3 reported high frequency of Staphylococcus
aureus (29%) and low frequency of Streptococcus pneumoniae
(9%) in intubatedpatientswithNHAP;however, in this previous
study, bacteriological examination was performed using sam-
ples taken during bronchoscopy and the presence of Strepto-
coccus pneumoniae antigen in urine was not included in the
diagnostic criteria. Sopena et al.24 evaluated 165 non-
intubated patientswith HAP, and found that themost common
causative organism is Streptococcus pneumoniae (9.7%) fol-
lowedbyEnterobacteriaceae (4.8%),P. aeruginosa (4.2%),Aci-
netobacter sp (4.2%), Staphylococcus aureus (3%); however, in
this study quantitative analysis of sputum culturewas not per-
formed. In the present study, the diagnostic criteria included
sputum Gram’s staining, quantitative evaluation of sputum
culture and measurement of urinary antigen for the diagnosis
of bacterial pathogens. The strict diagnostic criteria may ex-
plain accurate differences of frequency of bacterial pathogens
between non-intubated patients with HAP and NHAP.25,26In summary, the results of the present study showed that in
the non-intubated patient, the causative microorganism of
HAP differed from that of NHAP, with infection by Streptococ-
cus pneumoniae being more common in NHAP, infection with
Staphylococcus aureus, Enterobacteriaceae and P. aeruginosa
beingmore common in HAP, and infectionwithC. pneumoniae
and Cytomegalovirus being detected in both groups of
patients. In addition, the NHAP population had a frequency
of MDR pathogens that was less than 10% of the population.
This study also showed that performance and nutritional
status, oxygenation index, and the degree of dehydration are
important independent prognostic factors in both NHAP and
HAP patients. These findings have important implications for
the therapy of NHAP. Since many non-intubated patients
with NHAP are not infected with MDR, Staphylococcus aureus,
and enteric gram-negatives, it may not be necessary to treat
this population the same way as those with late-onset HAP,
as suggested in the ATS/IDSA nosocomial pneumonia guide-
lines. In fact, most of these patients could be treated with
a community-acquired pneumonia regimen and thus avoid
use of an excessively broad approach to therapy. Future stud-
ies areneeded tobetter definewhichNHAPpatients, including
those treated in thenursinghome, those treatedwithmechan-
ical ventilation, and those admitted to the hospital but not
intubated, are at risk for HAP pathogens, and which are not.
In addition, this study showed a high frequency of Chlamydo-
phila infection in both HAP and NHAP patients, and these find-
ings have implications for choosing effective empiric therapy
for both populations.
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